Evidence map›Paper›PMID 35083020›Full record

ArticleJournal of healthcare engineering2022

Quetiapine Combined with Sodium Valproate in Patients with Alzheimer's Disease with Mental and Behavioral Symptoms Efficacy Observation.

Zhihua Zhang, Jiating Xu, Penghao Xu, Wenjun Liu, Xianyan He, Kedeng Fu

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Journal of healthcare engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Zhihua ZhangSenile Psychiatry Department, The Third Hospital of Quzhou, Quzhou 324000, Zhejiang, China.
Jiating XuSenile Psychiatry Department, The Third Hospital of Quzhou, Quzhou 324000, Zhejiang, China.
Penghao XuSenile Psychiatry Department, The Third Hospital of Quzhou, Quzhou 324000, Zhejiang, China.
Wenjun LiuSenile Psychiatry Department, The Third Hospital of Quzhou, Quzhou 324000, Zhejiang, China.
Xianyan HeSenile Psychiatry Department, The Third Hospital of Quzhou, Quzhou 324000, Zhejiang, China.
Kedeng FuSenile Psychiatry Department, The Third Hospital of Quzhou, Quzhou 324000, Zhejiang, China.ORCID 0000-0003-1198-5776

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quetiapine combined with sodium valproate is an effective and more suitable drug treatment for Alzheimer's disease. At present, there are relatively few studies on the combined action mechanism of these two drugs. This study has certain practical value. Alzheimer's disease is a multifaceted, highly genetically heterogeneous neurodegenerative disease. The main clinical manifestations are memory loss, abnormal mental behavior, and loss of various cognitive functions. In order to improve the symptoms of patients with Alzheimer's disease, especially those with mental symptoms, this article combines quetiapine and sodium valproate, two commonly used drugs for the treatment of mental illnesses, and applies them to different levels of Alzheimer's and observes the results of the combination's curative effect. This article introduces Alzheimer's disease and its potential mental behaviors in the method section, and it also introduces the mechanism of action of quetiapine and sodium valproate. For the algorithm, this paper introduces a data mining algorithm to understand the effect of drug efficacy. In the experimental part, firstly, it introduces the experimental objects, the proportion of medicines, and the statistical methods. Secondly, this article covers adverse reactions, inflammatory factors and vascular endothelial indicators, Alzheimer's disease performance, MOAS score, treatment effect evaluation, and satisfaction surveys. It can be seen from the experiment that, in mental behavior, the experimental group decreased from 8.2 before treatment to 0.5, and the control group decreased from 7.1 before treatment to 2.6. It can be seen that the scores of the experimental group changed after receiving the treatment of quetiapine combined with sodium valproate.

Indexed as

Alzheimer DiseaseAntipsychotic AgentsNeurodegenerative DiseasesBehavioral SymptomsDibenzothiazepinesHumansQuetiapine FumarateValproic AcidAntipsychotic AgentsDibenzothiazepinesQuetiapine FumarateValproic Acid

Identifiers

PMID35083020
PMCPMC8786510
OpenAlexW4205124365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.